Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

NCT05129605 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05129605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05129605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Recruiting
Start date
February 12, 2020
Completion date
December 31, 2040
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atm gene mutation, brca1 mutation, brca2 mutation, genetic predisposition to disease, lynch syndrome, mmr mutation, prostate cancer, prostatic neoplasm